Diagnosis of Lyme Disease
For patients with a typical erythema migrans rash in an endemic area, diagnose clinically without laboratory testing; for all other presentations including neurologic, cardiac, or arthritic manifestations, use serum antibody testing with a two-tiered testing algorithm. 1
Clinical Diagnosis for Erythema Migrans
The most reliable approach depends entirely on the clinical presentation:
If the patient has one or more skin lesions compatible with erythema migrans (the "bull's-eye" rash) and lives in or visited a Lyme-endemic area, make the diagnosis clinically and start treatment immediately without waiting for laboratory confirmation 1. This is a strong recommendation based on moderate-quality evidence.
Laboratory testing in early erythema migrans is actually unreliable—only about one-third of patients with erythema migrans will have positive serology in acute-phase samples, increasing to only two-thirds during convalescence 3-4 weeks later 2. Testing these patients wastes time and money while delaying appropriate treatment.
Serologic Testing for Other Presentations
For suspected disseminated Lyme disease (neurologic, cardiac, or arthritic manifestations), serum antibody testing is the diagnostic method of choice 1:
Two-Tiered Testing Algorithm
The standard approach uses:
- First-tier: Enzyme immunoassay (EIA) or immunofluorescence assay
- Second-tier (if first-tier positive or equivocal): IgM and IgG Western blot
Modified two-tiered testing (MTTT) using two EIAs (where the second EIA replaces the Western blot, such as the C6 peptide ELISA) performs equivalently or slightly better than standard two-tiered testing, with 94-97% agreement and enhanced sensitivity in early disease 3. The most recent research from 2026 confirms MTTT has increased sensitivity compared to standard testing for early Lyme disease samples 4.
Performance Characteristics
- Early localized disease (erythema migrans): Poor sensitivity (30-40% in acute phase) 5, 2
- Disseminated and late disease: Excellent sensitivity—all 44 patients with neurologic, cardiac, or joint involvement had positive serology in prospective studies 2
Specific Clinical Scenarios
Lyme Neuroborreliosis
Use serum antibody testing, NOT PCR or culture of CSF or serum 1. This is a strong recommendation.
Test for Lyme disease when patients present with:
- Meningitis
- Painful radiculoneuritis
- Mononeuropathy multiplex
- Acute cranial neuropathies (especially CN VII, VIII)
- Spinal cord inflammation with radiculitis
- AND plausible tick exposure in endemic areas 1
When NOT to Test
Do not routinely test for Lyme disease in patients with 1:
- Amyotrophic lateral sclerosis
- Relapsing-remitting multiple sclerosis
- Parkinson's disease
- Dementia or cognitive decline
- New-onset seizures
- Psychiatric illness
- Developmental or behavioral disorders in children
- Nonspecific brain MRI white matter abnormalities without other clinical support
These are strong recommendations—testing these patients leads to false positives and inappropriate treatment.
Atypical Skin Lesions
If skin lesions are suggestive but atypical for erythema migrans, perform antibody testing on an acute-phase serum sample, followed by a convalescent-phase sample 2-3 weeks later if the initial result is negative 1. Avoid PCR or culture of blood/skin samples as they lack sensitivity.
Critical Pitfalls to Avoid
- Never test asymptomatic patients after a tick bite 1—this leads to false positives and unnecessary treatment
- Don't order serologic testing for typical erythema migrans—you'll delay treatment and the test will likely be negative anyway
- Don't use direct detection methods (PCR, culture) for routine diagnosis—they lack sensitivity except in specific research settings 1
- Recognize that positive serology cannot distinguish active from past infection 4—interpret results in clinical context
- In endemic areas where both Lyme disease and STARI (Southern Tick-Associated Rash Illness from lone star ticks) occur, treat as Lyme disease when you cannot distinguish between them 1
The key principle: Lyme disease diagnosis is fundamentally clinical, with serology serving as confirmation for disseminated disease, not as a screening tool.